What is Sandostatin® LAR® (octreotide acetate) used for?
SANDOSTATIN LAR is indicated for the treatment of:
Patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours (e.g. carcinoid tumours with features of the carcinoid syndrome) or patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded1
Patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective1
Patients with TSH-secreting pituitary adenomas:1
when secretion has not normalised after surgery and/or radiotherapy
in patients in whom surgery is inappropriate
in irradiated patients, until radiotherapy is effective.
Resources for you:
Reconstitution and preparation of SANDOSTATIN LAR
Reconstitution and preparation of SANDOSTATIN LAR
A guide on how to prepare and administer SANDOSTATIN LAR.
How to administer and prepare SANDOSTATIN LAR
A step-by-step video on how to prepare and administer SANDOSTATIN LAR.
Resources for your patients:
SASLAR - Home - patient guide - resource card
Your guide to SANDOSTATIN LAR
A guide to help you understand the treatment options you may be offered with SANDOSTATIN LAR.
Sandostatin LAR SmPC
TSH, thyroid-stimulating hormone.
Reference
SANDOSTATIN® LAR® Summary of Product Characteristics.
UK | February 2025 | FA-11214504
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
